Sumatriptan (Imitrex)

Triptan (5-HT1B/1D Agonist)prescriptionoral · inferred

Selective serotonin 5-HT1B/1D receptor agonist for acute migraine treatment. Available as oral, subcutaneous, and nasal formulations. Oral bioavailability only 14% due to first-pass metabolism; subcutaneous bioavailability is 96%. Does not prevent migraines; used only for acute attacks.

Projected serum levels — 50 mg, as needed (shown daily)

Maintenance schedule: 50 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 4.0 mg, trough ≈ 0.013 mg body load. Population-based estimate over 15 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: Triptan (5-HT1B/1D Agonist)
Route modeled: Oral
Model confidence: inferred
Half-life: 2.5 h
Common dose: 50 mg
Suggested maximum: 200 mg/day
Reference dose range: 25–200 mg (single dose)
Suggested cadence: as needed (shown daily)
Validated against: 100 mg oral — Cmax 0.070 mg/L at 2 h

Documented interactions

danger
1P-LSD (1-Propionyl-LSD) + Sumatriptan (Imitrex) Serotonin risk
1P-LSD (1-Propionyl-LSD) and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
25I-NBOMe + Sumatriptan (Imitrex) Serotonin risk
25I-NBOMe and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Sumatriptan (Imitrex) Serotonin risk
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Sumatriptan (Imitrex) Serotonin risk
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
3-MeO-PCP (3-Methoxyphencyclidine) + Sumatriptan (Imitrex) Serotonin risk
3-MeO-PCP (3-Methoxyphencyclidine) and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
4-AcO-DMT (Psilacetin) + Sumatriptan (Imitrex) Serotonin risk
4-AcO-DMT (Psilacetin) and Sumatriptan (Imitrex) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 78 modeled interaction pairings for sumatriptan (imitrex) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Treatment of migraine attacks with sumatriptan The Subcutaneous Sumatriptan International Study Group · New England Journal of Medicine, 1991 DOI
Landmark NEJM trial demonstrating subcutaneous sumatriptan relieved migraine symptoms in >70% of patients at 60 minutes and >90% at 120 minutes, establishing triptans as standard acute migraine therapy.
Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine Pfaffenrath V et al. · Journal of Neurology, 1998 DOI
Dose-response study showing sumatriptan 50 mg and 100 mg were significantly superior to 25 mg and placebo at 4 hours, defining optimal oral dosing for acute migraine treatment.
Sumatriptan clinical pharmacokinetics Scott AK · Clinical Pharmacokinetics, 1994 DOI
Comprehensive pharmacokinetic review establishing sumatriptan half-life of ~2 hours, 14% oral bioavailability, 96% subcutaneous bioavailability, and hepatic MAO-A metabolism.

3 published studies referenced in the app, each with a plain-language summary.